Valuation: Alumis Inc.

Market Cap 3.19B 2.8B 2.58B 2.41B 4.53B 301B 4.61B 30.99B 12B 148B 11.98B 11.72B 516B P/E 2026 *
-8.71x
P/E 2027 * -9.16x
Enterprise Value 2.66B 2.33B 2.15B 2.01B 3.77B 251B 3.84B 25.8B 9.99B 124B 9.98B 9.76B 429B EV / Sales 2026 *
340x
EV / Sales 2027 * 118x
Free-Float
96.2%
Yield 2026 *
-
Yield 2027 * -
1 day+3.02%
1 week+5.08%
Current month+19.68%
1 month+15.76%
3 months-1.79%
6 months+135.64%
Current year+164.86%
1 week 22.96
Extreme 22.96
25.94
1 month 18.36
Extreme 18.36
25.94
Current year 7.85
Extreme 7.85
30.6
1 year 2.92
Extreme 2.92
30.6
3 years 2.76
Extreme 2.7601
30.6
5 years 2.76
Extreme 2.7601
30.6
10 years 2.76
Extreme 2.7601
30.6
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 61 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 62 2021-04-30
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Date Insider Type Main position Quantity % Market Cap.
05-21Fiscal year

Chief Technology Officer

53,704 0.0468%
03-31
Foresite Capital Management LLC
OthersCompany 4,103,630 3.5738%
03-31
Foresite Capital Management LLC
OthersCompany 4,103,630 3.5738%
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%+5.08%+683.33% - 3.19B
+1.23%+2.25%+65.45%+121.01% 55.35B
+1.58%+14.12%+72.87%+85.18% 51.92B
+0.55%-0.21%-15.20%-15.83% 22.76B
+2.10%+7.97%+4.64%+434.73% 22.64B
-0.18%+7.48%+32.16%-14.07% 17.36B
-1.45%+3.30%+27.83%-34.96% 16.1B
+3.02%+12.74%+143.33%+308.04% 13.96B
+3.16%+7.00%+27.51%+182.35% 13.38B
+1.31%+6.52%+28.62% - 12.27B
Average +1.33%+5.93%+107.05%+133.31% 22.89B
Weighted average by Cap. +1.18%+6.55%+57.10%+124.32%

Financials

2026 *2027 *
Net sales 7.82M 6.87M 6.33M 5.91M 11.09M 737M 11.3M 75.89M 29.4M 364M 29.35M 28.71M 1.26B 23.83M 20.94M 19.29M 18.04M 33.83M 2.25B 34.45M 231M 89.65M 1.11B 89.51M 87.55M 3.85B
Net income -375M -329M -303M -284M -532M -35.37B -542M -3.64B -1.41B -17.44B -1.41B -1.38B -60.59B -397M -349M -321M -300M -563M -37.44B -573M -3.85B -1.49B -18.46B -1.49B -1.46B -64.14B
Net Debt -534M -469M -433M -404M -759M -50.43B -772M -5.19B -2.01B -24.86B -2.01B -1.96B -86.39B -371M -326M -300M -281M -526M -34.98B -536M -3.6B -1.39B -17.25B -1.39B -1.36B -59.93B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
226
Date Price Change Volume
26-06-26 US$25.86 +3.30% 288,646
26-06-25 US$25.03 +0.72% 1,117,307
26-06-24 US$24.85 +1.39% 956,385
26-06-23 US$24.51 -0.37% 1,185,461
26-06-22 US$24.60 +5.08% 1,435,836
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
25.03USD
Average target price
40.10USD
Spread / Average Target
+60.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock